Trial Profile
A prospective randomised controlled trial assessing the efficacy of intravitreal bevacizumab in patients with minimally classic and occult choroidal neovascularisation secondary to age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms BeMOC
- 04 Dec 2015 New trial record